A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
Số trang: 13
Loại file: pdf
Dung lượng: 2.48 MB
Lượt xem: 11
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Rucaparib has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. However, the long-term safety of rucaparib in large sample population was unknown. The presented study aimed to evaluate rucaparib-associated adverse events (AEs) according to the real-world pharmacovigilance database.
Nội dung trích xuất từ tài liệu:
A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
Nội dung trích xuất từ tài liệu:
A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Adverse event Data mining Disproportionality analysis Interquartile range Primary peritoneal cancerGợi ý tài liệu liên quan:
-
17 trang 183 0 0
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 141 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 112 0 0 -
12 trang 91 0 0
-
19 trang 74 0 0
-
17 trang 62 0 0
-
Bài giảng Khai phá dữ liệu (Data mining): Chương 8 - ĐH Bách khoa TP.HCM
8 trang 44 0 0 -
60 trang 39 0 0